These findings suggest that upregulated BCL11A hub gene expression in childhood ALLs may lead to MLL-r ALL development and BCL11A represents a new potential therapeutic target for childhood MLL-r ALL. Here, KMT2A is linked to acute lymphoblastic leukemia.